Global Metagenomic Sequencing Market - 2022-2029

Market Overview

Metagenomic Sequencing Market is expected to grow at a CAGR of 19.3% during the forecasting period (2022 - 2029). Metagenomics is a research field where genomic analysis of microbial DNA from environmental communities is studied. Metagenomic sequencing techniques enable scientists to analyze genes in a given sample. The method allows researchers to assess bacterial diversity and identify the presence of microbes in various environments. Steps involved in metagenomics sequencing include DNA extraction, library preparation, sequencing, assembly, annotation, and statistical analysis.

The Metagenomic Sequencing market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Metagenomic Sequencing segmentation by product & service, workflow, and application. It also provides metagenomic sequencing market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global metagenomic sequencing market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global metagenomic sequencing market growth driven by certain factors such as advanced technological platforms and improved genomic tools, increasing initiatives and funds by government and private organizations to large scale projects of sequencing are among the key factors driving the market growth.

Advanced technological platforms and improved genomic tools, is expected to drive the global metagenomic sequencing market during the forecast period;

One of the major factors driving the growth of the metagenomic sequencing market is the continuous development of faster sequencing techniques and advancements in different methods to cope with the huge data generated, which are expanding researchers' capacity to analyze microbial communities from an unlimited variety of environments.

The growing adoption of advanced bioinformatics tools, high throughput screening (HTS) methods, recovery of novel drugs, and development of cost-effective technologies such as next-generation sequencing (NGS) are driving the market growth. The development of Next Generation DNA Sequencing (NGS) technology has driven molecular biology research, leading to several discoveries and new insights. Next-generation DNA sequencing technology goes beyond long-established DNA sequencing with its applications that reach across the principles of molecular biology.

On May 28, 2019, a precision medicine biotechnology company, Macrogen, Inc. received South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and designated as a clinical trial specimen analysis institution. It would benefit Macrogen with improvised clinical diagnostic metagenomics.

Hence, increasing technological advancements regarding DNA sequencing is expected to drive market growth over the forecast period.

Increasing initiatives and funds by government and private organizations to large scale projects of sequencing

The growing awareness of genetic disorders and increasing government initiatives and funds for large-scale projects of sequencing are among the major factor driving the growth of the global metagenomic sequencing market. For instance, in 2019, QIAGEN got into a partnership with multiple organizations in the UK to support and establish its global genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will aim at innovation in life sciences, translational sciences, and the molecular diagnostics field.

Also, in November 2019, The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, France, Sweden, Denmark, Latvia, and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, skin, mouth, reproductive tract, and other organs in the next 3-5 years to draw a microbiome map of the human body and build the world's largest database of the human microbiome.

Factors hampering the growth of the metagenomic sequencing market

However, the market growth is hampered by several factors such as growing concerns towards the standardization and accuracy of diagnostic testing, its requirement for parallel advancement in various isolation and identification techniques, more efficient & robust bioinformatics tools, and lack of skilled professionals.

Segmentation Analysis

The shotgun metagenomic sequencing technology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

By technology, the metagenomic sequencing market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de-novo assembly, and metatranscriptomics. Out of all these segments, the shotgun metagenomic sequencing technology is growing at the fastest growth rate over the forecast period, due to the growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, several advantages offered by shotgun sequencing compared with other techniques, and the increasing number of metagenomic sequencing-based research activities. Shotgun sequencing can detect low abundance members of microbial communities. Shotgun metagenome sequencing can target all genes from all organisms found in an environmental sample, in contrast to the whole sequencing and targeting all genes from only one organism.

Geographical Analysis

North America region holds the largest market share of the global Metagenomic Sequencing market

North America region is dominating the global metagenomic sequencing market accounted for the largest market share in 2019, owing to technological advancements in the next-generation sequencing procedures along with its increasing applications, favorable initiatives by government and private bodies for the development and adoption of NGS-based metagenomics technologies, the wide adoption of metagenomic diagnostics in the region, and rising awareness of metagenomics sequencing services. The market players are collaborating to introduce new procedures with innovative technology. For instance, In 2019, Illumina and Thermo Fisher Scientific (U.S.) entered into a commercial agreement for the sales of Thermo Fisher's Ion AmpliSeq technology to researchers who use Illumina's NGS platforms.

Competitive Landscape

The metagenomic sequencing market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, DNAstar, Inc., Eurofins Scientific, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Brooks Automation, Inc. (GENEWIZ), Perkinelmer, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the metagenomic sequencing market globally. For instance,

In 2019, Illumina acquired Pacific Biosciences, one of the leading providers of sequencing systems. This helped Illumina strengthen its sequencing product portfolio.

In 2019, Illumina acquired Edico Genome, a software provider for NGS.

In 2019, Microba had partnered with Macrogen to develop microbiome research services for international markets.

In 2019, Eurofins Scientific acquired TestAmerica, a leading environmental testing laboratory group in the US. This helped Eurofins strengthen its presence in the US market.

In November 2018, Brooks Automation, Inc. acquired the GENEWIZ group which will improve the company's global services of metagenomics sequencing.

In 2017, QIAGEN acquired Microsoft Corporation (US), management, visualization, and analysis software provider for bioinformatics, NGS, and cancer genomics.

COVID-19 Impact Analysis

The metagenomic sequencing market is positively impacted by COVID-19 as, throughout the COVID-19 pandemic, testing is a critical component of the response and rapidly increasing, which enables rapid identification and isolation of infected individuals. The Majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus only.

Next-generation sequencing (NGS) of the COVID-19 virus is providing powerful metagenomic data, that is combined with clinical data to search for effective treatments. Continous genomic and epigenomic analysis of SARS-CoV-2 is critical, used to determine the number of virus strains, how the virus is spread into new regions, number of introductions of the virus if there is community spread of the virus if outbreaks are linked, and how the virus is evolving.

Oxford Nanopore Technologies is doing the Metagenomic analysis of SARS-CoV-2 respiratory samples via Sequence-Independent Single Primer Amplification (SISPA) and nanopore sequencing.

Industry Analysis

The global metagenomic sequencing market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, clinical trials, pricing analysis etc, unmet needs, reimbursement analysis.

Key Companies to Watch

Illumina, Inc

Overview: Illumina, Inc. was incorporated in April 1998, and headquarter located in San Diego, California. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serve the sequencing, genotyping and gene expression, and proteomics markets.

Product Portfolio: The company's product portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. Illumina also offers metagenomic sequencing services, which further strengthens its market position.

Key Development: In 2019, Illumina and Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to generate one of the largest ancient genome datasets. This partnership will also help explore the relationship between the evolutionary history of select mental & neurological disorders and infectious pathogens.

The global metagenomic sequencing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.